- Home
- QCLS vs ALGS Comparison
QCLS vs ALGS Comparison
Compare QCLS & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QCLS | ALGS |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | United States | United States |
| Employees | 2 | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.1M | 34.6M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | QCLS | ALGS |
|---|---|---|
| Price | $3.63 | $6.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $39.33 |
| AVG Volume (30 Days) | ★ 240.8K | 108.5K |
| Earning Date | 04-15-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.30 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,186,000.00 |
| Revenue This Year | N/A | $32.20 |
| Revenue Next Year | N/A | $4.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.50 | $4.80 |
| 52 Week High | $8.17 | $13.69 |
Technical Indicators
Market Signals| Indicator | QCLS | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 43.36 | 66.21 |
| Support Level | $3.45 | $6.25 |
| Resistance Level | $3.90 | $6.82 |
| Average True Range (ATR) | 0.26 | 0.52 |
| MACD | -0.02 | 0.17 |
| Stochastic Oscillator | 15.87 | 78.08 |
Price Performance
Historical ComparisonAbout QCLS Q/C Technologies Inc.
Q/C Technologies Inc is engaged in building blockchain and cryptocurrency infrastructure that is faster and more energy-efficient through quantum-class laser-based computing. The company uses laser-based processors inspired by quantum technology that can solve complex problems. By combining photonic computing with cryptocurrency systems, the company creates powerful and sustainable solutions for the next generation of blockchain applications.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.